Mutational Status of

Autor: Sara, Lahoz, Adela, Rodríguez, Laia, Fernández, Teresa, Gorría, Reinaldo, Moreno, Francis, Esposito, Helena, Oliveres, Santiago, Albiol, Tamara, Saurí, David, Pesantez, Gisela, Riu, Miriam, Cuatrecasas, Pedro, Jares, Leire, Pedrosa, Estela, Pineda, Antonio, Postigo, Antoni, Castells, Aleix, Prat, Joan, Maurel, Jordi, Camps

Publikováno v: Cancers. 14(23)

Next-generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metasta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ee01e7aed2cdc141bc73a023c9766f7a
https://pubmed.ncbi.nlm.nih.gov/36497403

Circulating tumor DNA profile in pancreatic ductal adenocarcinoma (PDAC) and potential targeted therapy

Autor: Francis Esposito, David Pesantez, Laura Angelats, Alberto Indacochea, Joan Martinez-Vidal, Alba Cochs, Alexis Perez, Pol Sole i Bentz, Debora Moreno Fernandez, Iris Faull, Mary Luz Campillo, Lidia Garcia-Losada, Angélica Rodríguez, Pilar Vicente, Miguel Nogué, Iván Victoria, Aleix Prat, Tamara Sauri, Javier García-Corbacho

Publikováno v: Journal of Clinical Oncology. 40:4152-4152

4152 Background: Despite huge efforts patients (pts) with advanced PDAC, still have a dismal long-term prognosis. The lack of available good-quality tissue samples for next generation sequencing (NGS) prevents from finding actionable alterations that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b1ebb94d4174d533555e7e6a7c32c29
https://doi.org/10.1200/jco.2022.40.16_suppl.4152

92P First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)

Autor: J. Martínez-Vidal, S. Muñoz, Alberto Indacochea, I. Victoria Ruiz, I. Faull, Francis Esposito, N. Basté, N. Reguart Aransay, T. Sauri, P. Sole Bentz, D. Moreno, Laura Mezquita, S. Castillo, Javier Garcia-Corbacho, L. Angelats, M.L. Campillo, M. Nogué, H. Oliveres, Nuria Viñolas, Aleix Prat

Publikováno v: Annals of Oncology. 32:S396-S397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::209c69fa6069287707abf53bdfd340bd
https://doi.org/10.1016/j.annonc.2021.08.372

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Autor: Adela Rodriguez, Ferran Torres, Francis Esposito, H. Oliveres, Joan Maurel

Publikováno v: Journal of Clinical Medicine, Vol 10, Iss 746, p 746 (2021)
Journal of Clinical Medicine
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

The approval of a new drug for cancer treatment by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is based on positive, well-designed randomized phase III clinical trials (RCTs). However, not all of them are analyze

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e081b3bb42ce3e9aa5405bf3ca7df2
https://pubmed.ncbi.nlm.nih.gov/33668473

1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer

Autor: Francis Esposito, D. Pesántez, T. Pascual, Dianny Martínez, Andreu Prat, C. Fillat, H. Oliveres, S. López, T. Sauri, Elia Seguí, C. Teixido Febrero, D. Momblán, H.K. Oberoi, J.C. Laguna, J. R. Guerrero, A. Pérez, Miriam Cuatrecasas, Esther Sanfeliu, Gloria Fernández-Esparrach, Fara Brasó-Maristany

Publikováno v: Annals of Oncology. 31:S922-S923

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bcbfffa970cd20991774dc0332a9b72
https://doi.org/10.1016/j.annonc.2020.08.1987